Alimentary Pharmacology & Therapeutics

Papers
(The H4-Index of Alimentary Pharmacology & Therapeutics is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC152
152
Letter: Gut microbiota—An overlooked therapeutic target in the prevention of post‐operative recurrence of Crohn's disease147
AP&T: Editors' Declarations of Interest116
Safety of an investigational formulation of budesonide (budesonide oral suspension) for eosinophilic oesophagitis: an integrated safety analysis of six phase 1–3 clinical trials110
88
Issue Information84
Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise—Authors' Rep76
Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis72
Letter: time to consider Pneumocystis jirovecii pneumonia prophylaxis in treatment of autoimmune hepatitis72
Issue Information71
69
Clinical Trial: Effect of Abdominal Vibration Combined With Walking Exercise Programme on Bowel Preparation in Older Patients With Constipation65
Meta‐Analysis: Pregnancies With Inflammatory Bowel Disease Complicated by Intrahepatic Cholestasis of Pregnancy64
Editorial: The future of managing drug induced liver injury64
Letter: Allostatic load—A potential key in the development of inflammatory bowel disease64
Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC61
Letter: Elderly onset inflammatory bowel disease—Treat to target approach is still warranted60
Editorial: Will MRI‐PDFF become the new standard for steatosis assessment in NAFLD? Authors' reply59
Editorial: STAT3 phosphorylation for tofacitinib monitoring in ulcerative colitis—a step towards precision medicine?58
Editorial: tradipitant has promise for treating gastroparesis but leaves gastric function alone—authors’ reply58
Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply58
Prevalence and clinical characteristics of patients with metabolic dysfunction‐associated fatty liver disease with hepatitis C virus infection—a population‐based study57
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues‐treated patients with chronic hepatitis B56
Healthcare burden and outcomes of hepatorenal syndrome among cirrhosis‐related hospitalisations in the US54
Editorial: rectal hyposensitivity in patients with hypermobile Ehlers‐Danlos syndrome and constipation—authors' reply53
Editorial: ustekinumab during pregnancy ‐ reassuring but still not enough52
Editorial: Plants against animals51
Liver resection versus microwave ablation for hepatocellular carcinoma in ideal candidates for ablation per Barcelona Clinic Liver Cancer staging: a propensity score matching and inverse probability o51
Editorial: biomarkers for alcohol‐related liver fibrosis—almost there?50
Editorial: liver disease in secondary care—‘money or your life’. Authors' reply50
Letter: is wireless oesophageal pH monitoring the best technique to evaluate night‐time reflux?48
Liver biopsy in the real world—reporting, expert concordance and correlation with a pragmatic clinical diagnosis48
Editorial: risk of pneumonia in IBD—reading between the lines!46
Letter: ductular reaction is a risk factor for prognosis of chronic hepatitis B complicated with non‐alcoholic fatty liver disease45
Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients45
Letter: Ozanimod and latent tuberculosis44
Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply44
Editorial: clinical outcomes in lean NAFLD – the devil is in the details. Authors' reply43
Editorial: dietary interventions to understand and treat primary sclerosing cholangitis—is gluten‐free diet a starting point?43
Editorial: coeliac disease follow‐up guided by gluten immunogenic peptides—are we there yet? Authors' reply43
Editorial: concurrence of coeliac disease with inflammatory bowel disease – is big data the final arbiter? Authors' reply42
0.1495668888092